23:44 , Nov 28, 2018 |  BC Extra  |  Company News

Management tracks: PolarityTE and Foamix hire first chief commercial officers

Regenerative biomaterial company PolarityTE Inc. (NASDAQ:PTE) hired Matt Kemp as chief commercial officer, a newly created position. He was CCO at Dendreon Pharmaceuticals LLC, now owned by Chinese conglomerate Sanpower Group Co. Ltd. (Nanjing, China)....
18:10 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Boston Biomedical reports detailed data from Phase III gastric cancer trial of napabucasin

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported data from the Phase III BRIGHTER trial in 714 patients with previously treated advanced gastric or gastroesophageal junction cancer showing that second-line...
22:55 , Oct 18, 2017 |  BC Extra  |  Company News

Management tracks: Gilead, Ipsen, Depomed

Gilead Sciences Inc. (NASDAQ:GILD) promoted Alessandro Riva to EVP of oncology therapeutics. He was SVP of hematology and oncology therapeutic area head. Before joining Gilead this year, he was head of global oncology development at...
20:49 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

Sumitomo's napabucasin unlikely to meet Phase III gastric cancer endpoint

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said an interim analysis by a DSMB showed that napabucasin (BBI608, BB608) was unlikely to meet the primary endpoint of improving overall survival...
18:36 , Jul 6, 2017 |  BC Week In Review  |  Clinical News

Boston Biomedical reports Phase Ib/II data for napabucasin in various cancers

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported data from various patient populations in a Phase Ib/II trial evaluating twice-daily oral napabucasin (BBI608, BB608) plus paclitaxel to treat advanced malignancies....
18:56 , Jun 30, 2017 |  BC Week In Review  |  Clinical News

Boston Biomedical reports updated data from Phase Ib/II trial of amcasertib in solid tumors

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported updated data from 14 patients with advanced adenoid cystic carcinoma (ACC) in an expansion cohort of the Phase Ib/II BBI503-101 trial showing...
18:55 , Jun 30, 2017 |  BC Week In Review  |  Clinical News

Boston Biomedical reports Phase Ib/II data for Nexavar combos in HCC

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported data from 14 patients with hepatocellular carcinoma (HCC) in the Phase Ib/II BBI608-503-103HCC trial showing that twice-daily 160 or 240 mg oral...
20:54 , Jun 26, 2017 |  BC Extra  |  Clinical News

Sumitomo's napabucasin unlikely to meet gastric cancer endpoint

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said an interim analysis by a DSMB showed napabucasin (BBI608) was unlikely to meet the primary endpoint in the Phase III BRIGHTER trial...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

Amcasertib: Updated Phase I data

Updated data from 13 patients with adenoid cystic carcinoma (ACC) in an extension cohort of the open-label, North American Phase I BBI503-101 trial showed that once-daily 10-300 mg oral amcasertib led to a median PFS...